Introduction

With recent advances in biomedical sciences, there have been many non-clinical trials using experimental animals to predict the effects of drugs, cosmetics, and chemicals. However, despite the utility of experimental animals, limitations in the accuracy of animal testing and associated ethical issues have given rise to the development of non-clinical tests using human cell sources. At present, organoid technology holds massive potential for biomedical applications including disease modeling, drug screening, biobanks, regenerative therapy, genetic screening, and personalized medicine [1,2]. Demand for organoid technology for in vitro toxicity and efficacy testing is also increasing in the pharmaceutical and cosmetic industries, leading to increasing demand for the commercialization of organoid technology in the life science industry.

An organoid is a miniature, self-organized, three-dimensional (3D) structure composed of tissues derived from various sources including tissues and stem cells. These cultures can be crafted to replicate a simplified version of a complex organ, or to express specific characteristics to produce certain types of cells. Since organoid technology has become an independent field of
research, a precise understanding of organogenesis in a dish will be a significant factor for the research and use of tissue or stem cell-derived organoids [3]. Since the 1900s, many scientists have agonized over the concept of the 3D architecture of organoids to establish the optimal conditions for the cellular composition and relationships in tissues observed in vivo. After the 2000s, organoids have been regarded as 3D structures growing from stem cells and consisting of organ-specific cell types that self-organize with spatially restricted lineage commitment [4]. Notably, Sato et al. [5] developed a sophisticated interstitial organoid resembling a crypt-villus structure in 2009. This finding became the spark for further developments in organoid research, leading to successful application in cultures of other tissue types such as stomach, pancreas, liver, colon, brain, lung, and heart from human tissue or pluripotent stem cells (PSCs) [6].

The recent pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a life-threatening crisis for all populations across the globe, but has ironically had a positive impact on the organoid market. Since organoids could accelerate translational research from non-clinical trials to clinical trials of drug development, studies with several tissue-specific organoids have demonstrated the value of organoids as a research platform for understanding the pathophysiology of COVID-19 in the body [7], and for evaluating the efficacy of drug or vaccine candidates [8].

In this review, we present not only insights into the state-of-the-art global trends of human organoid research and the organoid market, but also trends in the global organoid market and the factors driving the market. Moreover, the impact of the COVID-19 pandemic on global organoid research and market is analyzed as well.

---

**Current state of global organoid research and technology**

To investigate progress in global organoid research, PubMed publications on organoid research from 2010 to 2021 were analyzed. The results showed that the number of publications dramatically increased from the mid-2010s, and studies using stem cell-derived organoids have also increased significantly during the same period (Fig. 1).

1. **Stem cell and organoid research**

Among various cell sources for organoid generation, stem cells are considered the most promising because stem cells could easily mimic human development or organ regeneration in vitro with their self-renewal and differentiation potency. Furthermore, recent advances in gene editing technology (e.g., the CRISPR/Cas9 system) have facilitated disease modeling in stem cells by the correction or insertion of certain mutations.

Organoids could be established from PSCs or multipotent adult tissue (normal tissues or tumor tissues)-derived stem cells (adult stem cells [ASCs]). They make up organ-specific cell types that can spontaneously self-organize by forming clusters of cells, and these clusters spatially undergo finite lineage commitment to generate 3D cell assemblies that mimic the cellular compositions, architecture, and functions of the relevant organs [3,9]. The advantages and disadvantages of each stem cell source for organoid formation are summarized in Fig. 2.
Massive productivity is the biggest advantage of using PSCs in organoid generation based on embryonic stem cells (ESCs) and induced PSCs (iPSCs), unlimited potential for proliferation and differentiation. Furthermore, organoids from PSCs could be easily generated at a uniform size in vitro. A given number of PSCs first allows expansion and easily generates uniform PSC aggregate-like 3D structures with appropriate devices or platforms, and then, the uniform 3D PSC aggregates could go through several processes designed to mimic a series of developmental signaling networks that lead to differentiation into the specific cell types of interest in a dish with uniformly sized organoids. A PSC-derived organoid could also have a multicellular composition, constituting another advantageous feature of PSC-derived organoids. For example, single-cell RNA transcriptomes of kidney organoids from PSCs consist of 10% to 20% non-renal cells such as neuronal cells or muscle cells. Although this result might be attributed to off-target differentiation with undesired downstream consequences, it implies the possibility of generating multicellular organoids that mimic the native organs from PSCs without a mixture of different cell types in culture. However, PSC-derived organoids often show gene expression patterns that are closer to those of fetal tissues than those of their adult counterparts. For these reasons, current organoid technology from human PSCs might only be useful for studying early organogenesis in human developmental biology, and this limitation must be overcome to expand the applications of PSC-derived organoids.

In a standard establishment of human ASC-derived organoids, single stem cells or small cell clusters obtained from a biopsy of adult tissues (including tumors) are placed in a 3D matrix with a cocktail of growth factors mimicking essential aspects of the niche in which the cells usually reside. Unlike PSC-derived organoids, ASC-derived organoids consist of a well-defined and homogeneous structured cell population mainly found in the epithelium. In a landmark study published by the research group of Dr. Hans Clevers, complex 3D organized crypt-villus structures, which are now considered the first organoid, were generated from

Fig. 2. Characteristics of stem cell sources for organoid research. The initial cell sources used for organoid culture can be pluripotent stem cells (PSCs), including embryonic stem cells (ESCs), induced PSCs (iPSCs), and human adult stem cells (ASCs). Each cell type has associated advantages and disadvantages as a source for organoids. Each type of organoid develops with unique morphological and physiological features, and the process of developing organoids from PSCs optionally involves the presence of mesenchymal niches, in contrast with ASCs.
seeding of single intestinal stem cells [5]. Unlike iPSC-derived organoids, these organoids can be directly generated from dissected adult tissue fragments including diseased patient tissues. It has subsequently been reported that human ASC-derived organoids can be established from various tissue sources, including intestine, colon, liver, pancreas, stomach, lung, bladder, mammary gland, endometrium, prostate, fallopian tube, and others [2]. However, although it is easy to obtain all potentially necessary ASCs for organoid culture, human ASC-derived organoids normally have limitations in their differentiation potential and lifespan due to the restricted culture conditions for a specific tissue type [15].

In summary, PSCs are useful to explore early organogenesis in the developmental process and to differentiate the desired tissues in a dish, while organ-specific ASC-derived organoids are useful for adult tissue biology. Therefore, researchers could select the appropriate stem cell source suitable for their applications in diverse domains of biomedical research.

2. Main organoid types in current research

Currently, stem cell-derived organoids are established from the differentiation of stem cells cultured in a specialized microenvironment that aids the developmental process of certain tissues. Below, we present cases of generating each lineage-derived organoids from stem cells.

Research on ectoderm lineage-derived organoids has mainly focused on brain types. Lancaster et al. [16] reported the first self-assembled cerebral organoids, and subsequent studies established human PSC-derived brain-region-specific organoids, including the forebrain, choroid plexus, hippocampus, radial glial cell, midbrain, hypothalamus, and retina [17]. Furthermore, assemboids such as integrated human forebrain spheroids established from the fused form of dorsal and ventral forebrain organoids or thalamic and cortex organoids have also been reported [18]. Assemboids are a type of advanced technology in brain organoid research because they could facilitate the modeling of interactions between different brain regions and studying the assembly of neural circuits. In addition to brain organoids, other established types of ectodermal lineages such as skin organoids [19], inner ear organoids [20], and salivary gland organoids [21] have been reported. Further information on research on ectodermal lineage-derived organoids is described in Table 1 [20–46].

In the mesoderm lineage, the tissue type that has attracted the most interest is the circulatory system, including the kidney, heart, and vasculature. Takasato et al. [22,23] generated kidney organoids composed of renal interstitium and endothelium, and a kidney disease model in PSC-derived kidney organoids by gene editing was also reported [24]. Self-organizing chamber-like cardiac organoids from human PSCs [25] and murine heart organoids with multicellular compositions have also been established [47]. Cardiac organoids would be a leading tool for cardiac disease modeling and screening for cardiotoxicity [26,27]. Blood vessel organoids are a noteworthy area in vasculopathy. An article published in a prominent journal has reported the generation of blood vessel organoids in humans and mice [28], which addressed engineering of their perfusable in vitro vasculature system using chip technology to satisfy metabolic demands during development [29]. Table 1 presents further information on research on the mesodermal lineage-derived organoids.

In the endoderm lineage, a wide range of foregut-, midgut-, and hindgut-derived organoids have been reported. Lung organoids are the representative foregut lineage-derived organoids, and human PSC-derived lung organoids have been interconnected by a surprisingly delicate structure, including an upper airway-like epithelium with basal cells and ciliated cells, as well as a lower alveolar-like domain [30]. Notably, lung organoids have recently been used in models of SARS-CoV-2 infection in the respiratory tract [31]. Midgut- and hindgut-derived intestinal organoids were also generated from Lgr5\(^+\) stem cells, and further studies revealed that WNT3A and FGF4 signaling were involved in the generation of intestinal and colon organoids having villus and crypt-like structures [32,48]. Gjorevski et al. [49] identified that high stiffness of the matrix enhanced the expansion of intestinal organoids. Further information on research on the endodermal lineage-derived organoids is also described in Table 1.

3. Current applications of organoid research

Human organoids have diverse applications ranging from basic research to drug development. Here, we provide a comprehensive overview of the current applications of human organoids.

1) Studying tissue development

The distinct mechanisms of autonomous self-organization in tissue development, homeostasis, and regeneration in organoid models have been verified [2]. Thus, organoids could provide simple and easily accessible mini-organ systems for studying contributory factors related to complex morphogenesis. For instance, fetal pulmonary organoids have used to determine the signaling interplay between fibroblast growth factors and the vascular endothelial growth factor A pathway for endothelial network formation and the role of the sonic hedgehog pathway in epithelial and endothelial morphogenesis [50]. Moreover, organoids have provided a tool for discovering essential factors of stem cell differentiation [6,51]. For example, human adult crypt-derived Lgr5\(^+\) stem cells could re-establish intestinal epithelia in the absence of a
<table>
<thead>
<tr>
<th>Type</th>
<th>Cell type</th>
<th>Source</th>
<th>Key feature</th>
<th>Application</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ectoderm</td>
<td>Optic cup, vesicle and retina organoid</td>
<td>hESCs</td>
<td>· Formation of optic cup</td>
<td>· Developmental biology</td>
<td>[33,41]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hiPSCs</td>
<td>· Formation of rod and cone cells</td>
<td>· Disease modeling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>· RPE-to-NR-transition</td>
<td>· Biobanks for academic studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain organoid and forebrain spheroids (brain</td>
<td>hESCs</td>
<td>· Formation of cerebral cortical neurons, forebrain, hippocampus, radial glial cells</td>
<td>· Developmental biology</td>
<td>[35–37]</td>
</tr>
<tr>
<td></td>
<td>assembloid)</td>
<td>hiPSCs</td>
<td>· Modeling human microcephaly, Timothy syndrome, and ZIKV infection</td>
<td>· Disease modeling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>· Drug screening</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Skin organoid</td>
<td>hESCs</td>
<td>· Formation of epidermis and dermis layer capable of developing new hair follicle</td>
<td>· Developmental biology</td>
<td>[42]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hiPSCs</td>
<td>· Formation of nascent mechanosensitive tough complexes of sensory neurons and Schwann cells that target Merkel cells</td>
<td>· Regenerative medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>· Omics profiling</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inner ear organoid</td>
<td>hESCs</td>
<td>· Formation of sensory epithelia</td>
<td>· Developmental biology</td>
<td>[20]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>· Formation of vestibular-like hair cells with electrophysiological properties similar to those of native sensory hair cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surface ectoderm</td>
<td>hASCs</td>
<td>· Developed ductal structures and mucin-expressing acinar-like cells</td>
<td>· Developmental biology</td>
<td>[21]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>· Formation of salivary glands in vivo within the mouse embryonic salivary gland mesenchyme</td>
<td>· Regenerative medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Salivary gland</td>
<td>hESCs</td>
<td>· Formation of metanephric and epithelial nephron progenitors</td>
<td>· Developmental biology</td>
<td>[22–24]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hiPSCs</td>
<td>· Use of human kidney organoids for the evaluation of nephrotoxicity</td>
<td>· Omics profiling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>· Drug toxicity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kidney organoid</td>
<td>hESCs</td>
<td>· Confirmation of regenerative capacity of immature human heart tissue</td>
<td>· Developmental biology</td>
<td>[25–27]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hiPSCs</td>
<td>· Formation of cardiac organoid similar to human fetal/neonatal heart tissue</td>
<td>· Disease modeling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>· Modeling regenerative response following cryoinjury</td>
<td>· Drug screening</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>· Modeling of myocardial infarction and genetic cardiomyopathy</td>
<td>· Omics profiling</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiac organoid</td>
<td>hESCs</td>
<td>· Exhibition of morphological, functional and molecular characteristic of human microvasculature</td>
<td>· Transplantation</td>
<td>[28,29]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hiPSCs</td>
<td>· DLL4 and NOTCH3 as key drivers of diabetic vasculopathy in blood vessels</td>
<td>· Developmental biology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>· Vascularized organoids on a chip</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blood vessel organoid</td>
<td>hESCs</td>
<td>· Formation of engraftable alveolar and airway-like structures through basal, ciliary, and secretory cells</td>
<td>· Developmental biology</td>
<td>[30,31,38]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hiPSCs</td>
<td>· Modeling of cystic fibrosis</td>
<td>· Regenerative medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>hASCs</td>
<td>· Modeling of SARS-CoV-2 infection</td>
<td>· Drug screening</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>· Modeling of a1-antitrypsin deficiency and Alagille syndrome</td>
<td>· Omics profiling</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endoderm</td>
<td>hESCs</td>
<td>· Formation of human gastric cancer and <em>Helicobacter pylori</em></td>
<td>· Developmental biology</td>
<td>[34]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hiPSCs</td>
<td>· Differentiation of gastric organoids into mucous and endocrine cell lineages</td>
<td>· Disease modeling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>human primary cells</td>
<td>· Omics profiling</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lung organoid</td>
<td>hESCs</td>
<td>· Formation of a more complete 3D hiPSC-LB organoid by HUVEC and mesenchymal cell co-culture</td>
<td>· Regenerative medicine</td>
<td>[43]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hiPSCs</td>
<td>· Modeling of SARS-CoV-2 infection</td>
<td>· Disease modeling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>hASCs</td>
<td>· Modeling of SARS-CoV-2 infection</td>
<td>· Omics profiling</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liver organoid</td>
<td>hiPSCs</td>
<td>· Formation of a more complete 3D hiPSC-LB organoid by HUVEC and mesenchymal cell co-culture</td>
<td>· Regenerative medicine</td>
<td>[43]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hASCs</td>
<td>· Modeling of SARS-CoV-2 infection</td>
<td>· Disease modeling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>hASCs</td>
<td>· Modeling of a1-antitrypsin deficiency and Alagille syndrome</td>
<td>· Omics profiling</td>
<td></td>
</tr>
</tbody>
</table>

(Continued to the next page)
mesenchymal compartment in a dish [5], although the interaction between intestinal epithelium and mesenchymal cells has been considered as an essential factor for intestinal morphogenesis [52]. Similar to intestinal organoid research, it was determined that the autonomous morphogenesis in optic cup organoids from PSCs did not require signals from an overlying surface ectoderm [33]. Organoids also facilitate knockout studies of essential genes that would not be feasible in vivo due to embryonic lethality, enabling in-depth research into the role of genes implicated in human genetic disorders.

2) Disease modeling

Unlike traditional 2D cell cultures, organoids could mimic human pathologies at the organ level and provide an effective model for human translational studies to develop practical applications of scientific discoveries in human diseases.

Firstly, human organoids could reproduce host-pathogen interactions in vitro. Human gastric organoids were used to study Helicobacter pylori infection by mimicking the virus infection in the stomach [34]. Zika virus infections were also investigated in brain organoids [35,36], and various chemicals that could mitigate the hypomorphic effect of Zika virus were discovered in the studies using Zika virus-infected human brain organoids [37]. In studies of intestinal infections, norovirus and rotavirus have been successfully grown in human intestinal organoid cultures [53,54], and infections of Salmonella typhi and Clostridium difficile, major intestinal bacterial pathogens, were also reproduced in cultured intestinal organoids [55,56]. More recently, organoids have provided valuable research tools in response to the SARS-CoV-2 pathogen. Several reports have successfully shown that SARS-CoV-2 could be infected and propagated in the primary human liver and gut organoids, as well as in PSC-derived blood vessel and kidney organoids [38,57,58]. Furthermore, COVID-19 pathogenesis was verified in organoids, and researchers have found that the viral receptor, angiotensin-converting enzyme 2, is the mechanism of entrance of SARS-CoV-2 into host cells, and that the pathogen could infect other tissues beyond the lung [59]. As seen in previous studies, the feasibility of organoids as effective infectious disease models in vitro has been well demonstrated, and they could be used as novel screening platforms to discover drugs against various infectious diseases. Further information on research that used organoids for infectious disease is described in Table 2 [12,31,53–57,60–63].

Human organoids also play a role in enhancing our understanding of human cancers because organoids recapitulate the information of the parental patients. Diverse ASCs from cancer patients have been cultured as cancer organoids [64], and to date, organoid biobanks have been acquired by cancer patient’s tissues,
including breast, lung, glioblastoma, neuroendocrine, kidney, gastric, liver, pancreas, bladder, prostate, and colon [65]. The biobank of cancer organoids has shifted the study of cancers to investigate the identification of predictive biomarkers and tumor pathophysiology such as mechanisms of metastasis, chemoresponsiveness of anti-cancer drugs, and tumor-immune cell interactions [66]. Furthermore, drug development workflows have been developed through high-throughput processes [65,67].

Finally, human organoids are available as a novel platform for exploring genetic diseases. Apart from the well-known genetic diseases, The Genome Aggregation Database has reported 4.6 million missense variants for disease-causing mutations [68]. However, only 2% of mutations have shown clinical interpretations from in vitro functional assays and transgenic mice, which often failed to describe disease outcomes in human patients. Therefore, an alternative approach for studying genetic diseases is required, and organoids could fulfill this goal. Schwank et al. [39] first manufactured gene-corrected intestinal organoids derived from biopsies of 2 different cystic fibrosis (CF) patients with a homozygous CFTR F508 deletion using CRISP-Cas9 technology, and later studies generated CF patient-derived iPSCs with their homozygous mutations corrected by CRISPR, and the resultant corrected iPSC-derived organoids showed the capacity to differentiate into airway epithelium with normal CFTR expression and function [69]. Yang et al. [70] also assessed the abnormal contractile functions resulting from a myosin heavy-chain 7 mutation (E848G) in familial cardiomyopathy using patient-specific iPSC-derived cardiac organoids and proved that gene correction in the iPSC-derived organoids with dystrophin mutations could be applicable to tissue replacement therapy [71]. Thus, genetic disease modeling using organoid technology is a useful tool for functional studies of certain mutations and potential therapeutic strategies for clinical management.

3) Drug screening
Disease modeling using organoids has naturally been linked with drug screening in the drug development process. Currently, high-throughput drug screening has been studied extensively
in the field of cancer organoids. Kita et al. [72] analyzed approximately over 2,000 compounds in bladder cancer organoid lines, and they found that disulfiram, an anti-alcoholism drug, showed potential for use against bladder cancer as well. Lampis et al. [73] also found the hypersensitivity to HSP90 inhibitors in MIR21-mutated cholangiocarcinoma. Cancer organoids could also be useful in screening for effective drugs in cancer patients. For example, colorectal cancer patients with different mutations have shown different responses to EZH2 inhibitors. Moreover, screening with colorectal cancer organoids has been successful in determining that organoids with ATRX and PAX2 mutations showed sensitivity against EZH2 inhibitors. In contrast, p53 mutation-bearing organoids were resistant to EZH2 inhibitors [74]. Moreover, the United States Food and Drug Administration has recently adopted an “organ-on-a-chip” system to screen for organ-specific or multi-organ toxicity of drugs, food additives, chemicals, cosmetics, and other compounds [75]. The use of organoid platforms for drug toxicity and safety testing might also be expended because of their effectiveness.

4) Regenerative medicine

Modern medicine has presented limited tissue supplies from healthy donors for tissue transplantation in many incurable diseases [1,3]. In this respect, organoid-based regenerative medicines have promising potential as an alternative approach to cell replacement therapies. Transplantation of kidney organoids in a mouse model resulted in vascularization of the mouse kidney with the formation of renal tubules [23], and intestinal organoid transplantation in a murine model resulted in colon regeneration [40]. Orthotopic transplantation of liver organoids demonstrated that human fetal hepatocyte organoids displayed high engraftment efficiency in a toxin-induced acute liver failure mouse model [76]. Human iPSC-derived glucose-responsive islet-like organoids generated endocrine-like cell types with the re-establishment of glucose homeostasis upon transplantation in diabetic NOD-SCID mice [77]. Furthermore, 3D bioprinting technology has been suggested as a new strategy to build a 3D tissue architecture for the use of organoids in regenerative medicine. Zhang et al. [78] successfully devised endothelialized myocardium and heart-on-a-chip using bioprinting, and additional studies have continued to be reported on the combination of 3D engineered and organoid technology to mimic the structures of real organs and to provide transplantable mini-organs [79].

Although dedicated efforts are required to apply organoids for therapeutic purposes, including enhancing integrity after transplantation and developing alternative animal-free synthetic matrices for clinical applications [80], organoids are undoubtedly an interesting model for the development of effective regenerative medicines.

Current state of the organoid market and commercialization

1. Overview of the global organoid market

Several experts in the science industry are forecasting that the global organoid market is marching forward at a rapid pace for the forecast period of 2020 to 2027 and is anticipated to reach 3,420.49 million United States dollars by 2027 with a compound annual growth (CAGR) of 21.7% [81,82]. The key factors driving the market are therapeutic and diagnostic models as alternatives to animal models, efforts in academia to adopt novel technologies, growing industry-academia collaborations for R&D, and advanced technology in 3D engineering. Another factor is an increase in the incidence and prevalence of infectious diseases with rapid changes in the environment (with the most recent example being the COVID-19 pandemic), and the application of organoids as therapeutic tools for COVID-19.

Based on organ types, the highest market share as of 2019 was for intestine organoids, followed in descending order by liver, stomach, pancreas, lung, kidney, and other organoids (Fig. 3). According to a market research report by an integrated market research platform, even though the intestinal segment captured the largest share of the global organoid market in 2019, the forecast for 2027 predicts that liver segment will hold the largest market share and that the kidney segment of the market will grow at the fastest rate (Fig. 3). However, the intestinal segment is being boosted by iPSC-derived intestinal organoid technology with the introduction of in vitro technical advances, including CRISPR-Cas9 genome editing technology, bioengineering technology, co-culture systems with aerobic bacteria, and virus-infected disease modeling [83], which will lead to an expected average annual growth rate of up to 21.8% by 2027. Many experts have suggested that the main reason for the current market position is due to inadequacies in health care systems, such as increasing outbreaks of recurrent infectious diseases resulting from poor sanitation, a higher rate of transmission, and insufficient public health institutions for effective management [84].

In terms of the applications of organoids, the highest share of the market in 2019 was occupied by developmental biology, followed in descending order by drug toxicity/efficacy testing, regenerative medicine, and others as of 2019 (Fig. 4) [85]. Developmental biology is the largest segment of applications in the global organoid market, and it is expected to grow at a CAGR of 22.8%.
by 2027. In the organoid industry, the field of development biology includes a diverse range of activities, such as the production of germ lines, embryo development, and adult organogenesis. In particular, studies of patient-derived organoid biology might accelerate the demand for medical research, and it would create new opportunities for regenerative medicine, and lead to advances in knowledge and tools for preclinical studies, including drug development and treatment strategy. Since epidemics became one of the top 10 causes of death according to the World Health Organization in 2016, the field of disease pathology, including infectious disease, is expected to grow with a CAGR of up to 20.6% by 2027. Organoid technology has proven its effectiveness in determining the infection route, action mechanisms, and pathophysiology of diverse viral pathogens such as rotavirus, norovirus, Zika virus, and respiratory syncytial virus [86]. Furthermore, the appearance of SARS-CoV-2 has expanded funding for research and development of antiviral drugs, as well as disease modeling using organoid technology. Thus, the field of infectious disease pathology is still expected to account for a high share of the human organoid market in 2027.

Fig. 3. Market share and size of the global organoid market by organ type. Organoids have high potential for growth in the global market. Based on organ types, the global organoid market is divided into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. (A) According to market share by organ type during the forecast period from 2019 to 2027, intestine organoids dominated the global organoid market share (23.3%) in 2019 and are expected to continue its dominance during the forecast period. The digestive system, including the liver, stomach, and pancreas, accounted for the next highest shares of the market (22.5%, 19.0%, and 13.3%, respectively) as of 2019, and liver organoids in particular are expected to have the highest market share in 2027. (B) In an analysis of market size by organ type, intestine and liver organoids have the highest value in terms of United States dollars (USD) in 2019’s global organoid market, but kidney organoids are expected to account for the highest cumulative annual growth rate in 2027.
applications, biotechnology including genetic engineering, tissue engineering, and biomaterial science are integrated into human organoids. Pharmaceutical and biotechnology companies are currently competing for success in the field of regenerative medicine with organoid technology. Thus, the use of organoids in the field of regenerative medicine will continue to grow around the world.

2. Cases of commercializing organoid technology

As the organoid market in various applications is expected to grow significantly, the demand for commercial human organoids will increase each year [87]. As a result, the number of companies that have commercialized organoid technology has increased, and the representative companies are as follows. Organome and Hubrecht Organoid Technology (HUB) has focused on organoid biobanking, while SUN Biosciences and System 1 Biosciences have developed a 3D robotic automation culture platform for organoid generation. Cellesce has provided a colorectal cancer organoid from colon cancer and breast cancer. The Living Biobank from HUB Organoid Technology has also offered a wide range of commercial organoids, CRISPR/Cas9 technology for genetic diseases with organoids, and drug response tests for clinical researchers. In addition to these organoid companies, the Human Cancer Model Initiative (HCMI) international consortium with American Type Culture Collection and HCMI
recently initiated a crucial step in commercializing organoids to produce and supply cancer organoids for research [88]. Another interesting company is QGel in Lausanne, Switzerland, which has developed over 100 synthetic extracellular matrix (ECM) libraries unique to each cell line and their organoid cultures [89]. Trevigen in Gaithersburg (MD, USA) has established the Organoid Resource Laboratory as its R&D department, through which it offers ready-made gastrointestinal organoids and the technical support to generate organoids and 3D cultures. STEMCELL Technologies, Corning, and R&D systems, as prominent key market players, have also supplied 3D engineering technology for the organoid manufacturing process. Table 3 presents a detailed summary of additional companies that have commercialized organoids and their business offerings.

3. Living Biobank library for organoids
The organoid biobank is a living biobank platform established by Dr. Hans Clevers as part of HUB. HUB has endeavored to be a world-leading central storage for a collection of organoids derived from both healthy donors and patients. Currently, several companies such as Epistem, Cellesce, Crown Biosciences, and STEMCELL Technologies have licensed organoid technology from the HUB. Their living organoid biobank has kept patient-derived liver, pancreatic, intestine, lung, and reproductive system organoids, as well as healthy organoids. These patient-derived organoids have been used to model major diseases such as cancer, CF, and infectious diseases. This centralized system has directly supplied researchers, clinicians, pharmaceutical companies, and other biomaterial companies. The organoid biobank is also managed with information from organoids, including registered patient details, storage conditions, and shipping with a tracking system [87,90]. Another global biobank business was recently initiated by the Human Individualized Treatment for CF project in Europe, which built a large-scale intestinal organoid biobank composed of approximately 500 rare mutant biopsies of CF patients from 17 different European Union (EU) countries and in turn tested candidate drugs on organoids [91].

4. The impacts of the COVID-19 pandemic on the global organoid market
Organoids are a crucial tool for understanding viral pathology, which prompted researchers to use organoids to strategize regarding predictions about the COVID-19 situation and its resolution. During the COVID-19 pandemic, researchers have proven the value of human organoids, including intestine, kidney, and lung organoids, as useful research platforms against SARS-CoV-2 [8]. Those results reflected the positive impact of enormous investments in R&D related to organoids. The Canadian government provided financial support for 47 projects including the organoid industry. In Europe, the EPIORGABOLISM project of the Marie Sklodowska-Curie Actions supported human resources to study the action of SARS-CoV-2 in kidney organoids [57], and the EU government provided finding for the identification of drugs capable of blocking the early stages of SARS-CoV-2 infection. In the aspect of technical advances during the COVID-19 pandemic, a research team at Kyoto University in Japan has succeeded in creating in vitro miniature bronchi from human iPSCs that could circulate air into the alveoli [92], and this model was used for evaluating an anti-flu drug, Avigan from Fujifilm Holdings Corporation, and several new antiviral drugs for treating COVID-19 [93]. Therefore, the relationships between researchers, government, and companies have dramatically strengthened to apply organoid technology for disease modeling, virus replication, new vaccines, and drug development during the pandemic. As a result, the recent advent of SARS-CoV-2 is expected to have a positive impact on the global organoid market.

Current limitations and future directions for organoid technology
Organoid research has evolved into the formation and study of various tissue organoids along with the development of stem cell technology (Fig. 5) [94,95]. Despite the rapid advances in organoid technology, the community is facing long-term challenges for a few reasons. First, current organoid technology remains incomplete from a researcher’s perspective. In detail, most organoids contain only an epithelial layer without exquisitely tissue-specific microenvironments such as vascular network, immune regulatory system, and nervous system [96]. Further, the traditional organoid culture in a dish has omitted a dynamic microenvironment with nutrient and gas delivery for appropriate development, which is a limitation of completely mimicking organs and the human body [97]. Second, PSC-derived organoids have shown limited maturation compared to adult organs or tissues. Recently, 3D technology has offered the organ-on-a chip, which could reproduce the physiological and mechanical functions of human organs. This platform might be considered as an effective system to solve the immaturity of PSC-derived organoids and could be applied to diverse organs including lung, gut, brain, heart, liver, skin, and muscle [98]. Additionally, suspension cultures by bioreactors play a role as a dynamic 3D cell culture platform for a variety of biomedical applications. Their dynamic process provides a better environment to obtain...
<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
<th>Major business details</th>
</tr>
</thead>
</table>
| 3Dnamics                      | US, Baltimore | • Founded by stem cell professional and neuroscientists at Johns Hopkins University in 2016  
• Develops new drug discovery and treatment for intractable nervous system diseases using 3D organoids  
• Approximately 0.1% of the drugs used in the preclinical trials are used in phase 1 clinical trials |
| CHA Biotech                   | Korea, Seongnam | • Focuses on gastrointestinal and colon organoid derived from adult stem cells  
• Creates customized organoids using cell lines and tissues provided by researchers |
| Cellesce                      | UK, Cardiff | • Focus on colorectal organoid derived from organoid biobank  
• Develop another organoid type including prostate, breast and others  
• Provide services on patient-specific genetic information and preclinical and clinical drug reactivity |
| Hubrecht Organoid Technology (HUB) | The Netherlands, Utrecht | • Is the only organization in the US that integrates organoid technology into pediatric research  
• Manages the Center for Stem Cell and Organoid Medicine (CuSTOM), which focuses organ development from embryos |
| R&D Systems                   | US, Minneapolis | • Manufacturing recombinant proteins, peptides, antibody and cell culture reagents including stem cell line and culture medium |
| Organoid Science              | Korea, Seongnam | • Korea’s first registered organoid company in 2018  
• Develops organoid-based regenerative therapy and drug screening platform  
• Develops organoid-based new drug screening platform  
• Distributes several mouse organoid lines and sells culture medium |
| STEMCELL Technology           | Canada, Vancouver | • Provides culture medium and material for 3D organoid culture  
• Provides experimental kits for organoids |
| T&R Biofab                    | Korea, Siheung | • Organoid development using 3D bioprinting technology  
• Focuses on organoid development and application technology |
| Cincinnati Children’s Hospital Medical Center | US, Cincinnati | • Is the only organization in the US that integrates organoid technology into pediatric research  
• Manages the Center for Stem cell and Organoid Medicine (CuSTOM), which focuses organ development from embryos |
| Trevigen                      | US, Gaithensburg | • Focuses on cancer and toxicology related products  
• Foundation of Organoid Research Institute in 2016  
• Provides experimental kits for organoids |
| QGel                          | Switzerland, Lausanne | • Provides over 100 synthetic extracellular matrix libraries for cultures of cell and organoid line  
• Provides more than 10 organ tissue types and cell lines for organoid formation |
| SUN Biosciences               | Switzerland, Lausanne | • Provides PEG-based hydrogel plates for 3D culture automation  
• Start-up company for neuropsychiatric drug discovery  
• Provides cerebral organoids and preclinical models of them |
| System 1 Biosciences          | US, San Francisco | • Provides iPSC-derived intestinal organoids for modeling of human intestinal disease  
• Optimizes successful generation of intestinal organoids from various patients  
• Develops tool for coronavirus-specific intestinal cell research |
| DefiniGEN                     | UK, Cambridge | • Provides high-quality recombinant cytokines and growth factors to support life science research, cellular therapy and regenerative medicine  
• Provides organoids and spheroid created by validated protocol for organoids and spheroids culture  
• Provides an e-learning course about cancer organoids and spheroids  
• Offers biopharmaceutical products to patients with end-stage glanular organ disease for alternative pharmacological therapy |
| Organoid Therapeutics         | US, Pittsburgh | • Develops organoid-based artificial organ technologies for translational medicine |
| PeproTech                     | US, New Jersey | • Provides high-quality recombinant cytokines and growth factors to support life science research, cellular therapy and regenerative medicine  
• Provides organoids and spheroid created by validated protocol for organoids and spheroids culture  
• Provides an e-learning course about cancer organoids and spheroids  
• Offers biopharmaceutical products to patients with end-stage glanular organ disease for alternative pharmacological therapy |
| Thermo Fisher Scientific      | US, MA, Waltham | • Provides high-quality recombinant cytokines and growth factors to support life science research, cellular therapy and regenerative medicine  
• Provides organoids and spheroid created by validated protocol for organoids and spheroids culture  
• Provides an e-learning course about cancer organoids and spheroids  
• Offers biopharmaceutical products to patients with end-stage glanular organ disease for alternative pharmacological therapy |
| Coming                        | US, New York | • Is a leading innovator in material science  
• Provides consumables such as plastic vessels, specialty surfaces, cell culture media and serum, as well as general labware and equipment that are used for advanced cell culture research, bioprocessing, and drug discovery |
| Merck KGaA                    | Germany, Darmstadt | • Provides human lung organoid culture system to enable human iPSCs to different into mature lung organoids  
• Provides natural hydrogels to support the formation, growth, and differentiation of stem cells and organoids |
| Nichirei Biosciences          | Japan, Tokyo | • Provides human lung organoid culture system to enable human iPSCs to different into mature lung organoids  
• Provides natural hydrogels to support the formation, growth, and differentiation of stem cells and organoids |

US, United States; UK, United Kingdom; 3D, three-dimensional; PEG, polyethylene glycol; iPSCs, induced pluripotent stem cells.
large-scale organoid culture with structural and transcriptional outcomes from existing restricted workflows [99] and it facilitates organoid culture with mechanical loading of nutrients and gas concentration to fulfill organogenesis and adult development. To date, multiple bioreactor classes have been designed for organoid generation, expansion, and tissue-specific differentiation. These processes might accelerate the maturation of cells or organs, as well as creating a 3D multicellular construction [99,100]. All these proofs of concept may indicate that organ-on-a-chip or bioreactors will be factors in the upcoming organoid market. Another limitation is that organoid culture depends on the ECM such as Matrigel or basement membrane of animal origin. The fact that currently used matrices are normally obtained from mouse tumor cell lines could be a major obstacle for clinical applications. Moreover, organoid culture with Matrigel might affect drug penetration into organoids embedded in Matrigel, and it remains controversial for the potential use of organoids in drug screening. Therefore, a priority of 3D bioengineering technology is to develop novel ECM products that can replace the current ECM as soon as possible, which will further boost the growth of organoid research and market.

From the market perspective, there are a few limitations that restrain the growth of organoid market. Although it is expected that organoid technology will bring innovations in drug development and regenerative medicine, current resources, including specialists, adequate infrastructure, and procedures, are limited. This problem may be attributed to the short experiences of research and commercializing organoid technology. Therefore, although the US, Europe, India, Japan, and Korea are leading the field of organoid technology, it is important to cultivate research specialists and skilled professionals to run, analyze, and verify research experiments to facilitate continuous growth of the organoid market globally.

Conclusion

In this review, we have presented an overview of global trends in organoid technology from research to industrial applications. As reviewed, the global market for organoids is growing significantly, and prospective organoid technology has substantial potential to provide a novel platform in various applications, including drug discovery, and developing regenerative medicine. Although or-
ganoid technology is very promising, standardization of organoid production, mass production of standardized organoids, and the development of effective cryopreservation technology for produced organoids are required for further development and commercialization of organoid technology. Therefore, if we overcome the limitations with a sober perspective on current obstacles facing organoid technology, tremendous social and economic benefits derived from creating organoid-related industries will be expected.

Notes

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Funding
This study was supported by grants from the National Research Foundation funded by the Ministry of Science and ICT of Korea (No. 2019M3A9H1103718).

Author contributions
Conceptualization: DHW, HL; Investigation: HL, DBC, JSI; Data curation: HL, DBC, JSI; Project administration: DHW; Writing-original draft: HL; Writing-review&editing: DHW.

ORCID
Hanbyeoel Lee, https://orcid.org/0000-0001-9671-315X
Jeong Suk Im, https://orcid.org/0000-0002-5292-2803
Da Bin Choi, https://orcid.org/0000-0002-1162-8982
Dong-Hun Woo, https://orcid.org/0000-0001-7470-018X

Data availability
Please contact the corresponding author for data availability.

References


72. Kita Y, Hamada A, Saito R, Teramoto Y, Tanaka R, Takano K, et al. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in...


95. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by de-